Creative Biolabs provides unrivaled expertise in antibody-drug conjugate (ADC) production. Offering enzymatic modified antibodies for conjugation is one of our featured services. We have built up one-stop comprehensive antibody and pharmaceutical platforms to perform antibody engineering and conjugation.
Figure: Enzyme-mediated modification and conjugation (Antibodies, 2015)
Enzymatic modified antibody can be used for site-specific conjugation. In this method, enzymes that recognize a specific amino acid tag are developed for site-specific antibody conjugation. Compared to conventional approaches, enzymatic conjugation permits more precise control over stoichiometry and conjugation sites which yields completely homogeneous conjugates. Generally, there are three strategies that are widely used for enzymatic modiﬁcation of antibodies in bioconjugation. It is optional that using bacterial transglutaminase (BTGase/MTGase) from Streptomyces mobaraensis for enzymatic ligation. Transglutaminase can catalyze the cross-linking of lysine and glutamine containing peptides by forming an isopeptide bond. BTGase can catalyze the coupling of glutamine side chains to alkyl primary amines. BTGase is robust, Ca2+ dependent and has high reaction rate compared to mammalian TGases. It can be used to couple lysine-containing substrates or cadaverine derivatized entities to an antibody. Another approach is to employ Sortase A (SortA)-mediated peptide coupling. SortA from Staphylococcus aureus recognizes a C-terminal pentapeptide sequence (LPXTG) which can be utilized to form an amide bond between threonine within the sequence and glycine in the N-terminus of the conjugation partner. Similarity, the sortase recognition sequence of Streptococcus pyogenes sortase A is LPXTA. The third strategy for enzymatic antibody modification is to use formylglycin generating enzyme (FGE), which recognizes a tag comprising a six-residue LCxPxR and oxidizes the cysteine to formylglycine, thereby creating a bioorthogonal aldehyde handle for site-specific chemical antibody conjugation.
As a global biotech company, Creative Biolabs can design and perform the most appropriate conjugation strategy to develop ADCs. Our professional teams with experts and years of experience in therapic agents manufacturing enable us to assist your researches about ADCs for scientific and clinical purposes.